Blockade of the renin-angiotensin and endothelin systems on progressive renal injury

Hypertension

Volumn 36, Issue 4, 2000, Pages 561-568

  Cao, Z ^a   Cooper, M E ^a   Wu, L L ^a   Cox, A J ^a   Jandeleit Dahm, K ^a   Kelly, D J ^a   Gilbert, R E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin II; Endothelin; Kidney failure; Transforming growth factors

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BMS 193884; BOSENTAN; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; IODINE 125; IRBESARTAN; PERINDOPRIL; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HYPERTENSION; KIDNEY FAILURE; KIDNEY INJURY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0033774846     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.36.4.561     Document Type: Article

References (41)

1. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
2. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys
3. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
4. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy
5. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system
6. Role of angiotensin II and bradykinin in experimental diabetic nephropathy: Functional and structural studies
7. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation
8. Vasoactive hormones and renal sclerosis
9. Role of endothelin in hypertension of experimental chronic renal failure
10. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
11. Effects of long-term angiotensin II AT(1) receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats
12. Validation in awake rat of a tail-cuff method for measurement of systolic blood pressure
13. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes
14. Evaluation of the Coomassie Brilliant blue G-250 method for urinary protein
15. Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs
16. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
17. Towards quantitative in situ hybridization
18. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus
19. Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-beta as a key mediator
20. Transforming growth factor-β in diabetic nephropathy
21. Cellular localization of endothelin receptor subtypes in the rat kidney following in vitro labelling
22. Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: A pilot study
23. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats
24. Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats
25. Class differences in the effects of calcium channel blockers in the rat remnant kidney model
26. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
27. Why is proteinuria such an important risk factor for progression in clinical trials
28. Pathophysiology of progressive nephropathies
29. Renoprotective therapy: Titration against urinary protein excretion
30. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy
31. Additive effects of losartan and enalapril on blood pressure and plasma active renin
32. Angiotensin II receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
33. Transforming growth factor-β in tissue fibrosis
34. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis
35. Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade
36. ETa receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat
37. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats
38. Blocking both type a and b endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney
39. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression
40. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth
41. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure